GRAPPA Members Laura Savage and Fabian Proft participated in a debate at the 2024 GRAPPA Annual Meeting titled "Managing MSK Symptoms in PsO Patients: Who Should be in the Driver Seat?" Now available in an article written by Medscape, we're curious to hear your thoughts on who should be in the driver seat! Read the article here 👉https:/https://lnkd.in/gKTxNUjD
Group for Research and Assessment of Psoriasis and Psoriatic Arthritis - GRAPPA
Non-profit Organizations
Seattle, Washington 1,096 followers
Forum for networking & communication between international researchers in rheumatology & dermatology, industry, & PRPs.
About us
Originally inspired by the Assessment in Ankylosing Spondylitis Working Group (ASAS), GRAPPA was formed in 2003. GRAPPA has pulled together many different groups, including preeminent researchers and thought-leaders in psoriatic arthritis (PsA) and psoriasis (PsO). In 2015 a team of Patient Research Partners was added to round out our perspective. The idea was to form a consortium of rheumatologists, dermatologists, radiologists, epidemiologists, patient representatives and others who would like to contribute to the field of PsA. At the inaugural meeting in 2003, a consensus exercise started the group toward prioritizing domains of inquiry in PsA and PsO. Subsequent annual meetings have focused on identifying and initiating research projects, advancing standardized criteria for psoriatic arthritis registries, and developing treatment guidelines for PsA. GRAPPA is a 501(c)3 nonprofit organization with offices in Seattle, WA and members from around the world. Today, more than 1000 thought-leaders participate in GRAPPA including rheumatologists, dermatologists, radiologists, geneticists, methodologists, epidemiologists, patient research partners, and biopharmaceutical industry representatives. Approximately 75 percent of our members live and work outside North America; creating a truly international effort.
- Website
-
www.grappanetwork.org
External link for Group for Research and Assessment of Psoriasis and Psoriatic Arthritis - GRAPPA
- Industry
- Non-profit Organizations
- Company size
- 2-10 employees
- Headquarters
- Seattle, Washington
- Type
- Nonprofit
- Founded
- 2003
- Specialties
- Medical research and education
Locations
-
Primary
Get directions
3213 W. Wheeler St. #35
Seattle, Washington 98199, US
Employees at Group for Research and Assessment of Psoriasis and Psoriatic Arthritis - GRAPPA
Updates
-
Great opportunity to submit #psoriasis related abstracts!
Don’t miss your chance to submit abstracts for the Psoriasis from Gene to Clinic meeting in December. Abstracts on all aspects of #psoriasis are invited for consideration by the Scientific Committee and must be submitted by August 1, 2024. For further information on abstract guidelines and how to submit, visit: https://lnkd.in/gp4sch4f #PsoriasisAbstract #PsoriasisEducation #PsoriasisResearch
-
-
We are thrilled to announce our upcoming Y-GRAPPA Virtual Mentor-Mentee meeting on August 9th! Join us for an insightful session with Dr. William Tillett from the University of Bath. 🗓️ Date: August 9th 🎤 Speaker: Dr. William Tillett, University of Bath 📚 Gain valuable insights and connect with peers! Don’t miss this opportunity to learn and grow together. Mark your calendars and get ready for an enriching experience! Register now at https://lnkd.in/gnnY4_UJ
-
-
Isaac Chang, a trainee from Hong Kong mentored by Lai Shan Tam, presented an abstract poster at the 2024 GRAPPA Annual Meeting and Trainee Symposium showing Secukinumab significantly improves Psoriatic Arthritis outcomes. After 1 year, patients on secukinumab showed reduced erosion progression, better partial erosion repair, and less enthesophyte growth compared to placebo. See his infographic summary below! #GRAPPA2024
-
-
We are thrilled to announce that the GRAPPA Annual Meeting and Trainee Symposium will take place for the first time in Latin America in 2025! 🥳Join us in beautiful Bogotá, Colombia, for a groundbreaking event filled with research, collaboration, and vibrant culture. Stay tuned for more details. We look forward to seeing you in Bogotá!
-
We would like to extend our heartfelt gratitude to each of you who attended the 2024 GRAPPA Annual Meeting in Seattle, whether in-person or virtually. Your presence and active participation were integral to the success of the event. This year's meeting was a remarkable gathering of minds, filled with insightful discussions, groundbreaking research, and invaluable networking opportunities. Your contributions, whether through presentations, discussions, or simply your enthusiastic participation, helped create an engaging and enriching experience for all. We are incredibly proud of the collaborative spirit that was evident throughout the meeting and are excited about the future directions and innovations in psoriatic disease research and treatment that were shared. #GRAPPA2024
-
-
-
-
-
5
-
-
Great opportunity for Derm residents and Rheum fellows!
Calling all #rheumatologists 📅 Save the date for the annual Dermatology Residents' and Rheumatology Fellows' Meeting on October 19-20 in Salt Lake City! This prestigious event offers an opportunity to advance your knowledge in the latest treatments and management of psoriasis and psoriatic arthritis. Enhance your expertise and collaborate with dermatology residents in this unique cross-disciplinary training experience. Don't miss out—apply now to elevate your practice and improve patient care! ➡️ https://lnkd.in/gQTuGA6R
-
-
Taking place the evening before the GRAPPA Annual Meeting in Seattle, the Arthritis Foundation is holding the Great West Rounds Summer 2024. You're invited to join GRAPPA Co-Vice President Joseph F. Merola, M.D. MMSc as a guest lecturer at this educational event for clinicians: https://lnkd.in/g5Tz3tYS
-
-
Great work to the team on this D2T-PsA project and many thanks to all who contributed to the surveys!
Rheumatologist member of Young-GRAPPA since 2021, with a research focus in psoriatic arthritis and medical education, participating in the Education Subcommittee. Currently, chair of Young-GRAPPA 2024-2025.
🚀 Exciting Update in the Psoriatic Arthritis Difficult-to-Treat from GRAPPA 🚀 Our latest publication regarding the difficult-to-treat (D2T) and complex-to-manage (C2M) project from the GRAPPA initiative has been published: "Deciphering Difficult-to-Treat Psoriatic Arthritis (D2T-PsA): A GRAPPA Perspective from an International Survey of Healthcare Professionals" 📈 The study captures diverse viewpoints from rheumatologists and dermatologists across 47 countries, providing a comprehensive understanding of the challenges in managing PsA. Key Insights: 1. Differentiating D2T-PsA and C2M-PsA: Our survey among 223 healthcare professionals reveals a strong consensus on the need to establish distinct definitions for D2T and C2M PsA. This differentiation is crucial for guiding precise and effective treatment strategies. 2. 🔍D2T-PsA and C2M-PsA, while related, are not mutually exclusive. D2T-PsA is seen as a subset within the broader C2M-PsA category, highlighting that it represents a truly treatment-refractory group needing distinct management approaches. 3. 🔬 90.5% of respondents support including objective signs of inflammation in the D2T-PsA definition, emphasizing the need for clinical, laboratory, and imaging assessments to guide treatment. 4.💡Treatment Failure Criteria: There are various opinions on treatment failure criteria, particularly regarding the number of therapies needed to classify PsA as D2T. This underscores the need for ongoing discussion to achieve a unified approach in the future. What This Means for Patients: By establishing clearer definitions for D2T and C2M PsA, we can better identify severe cases and tailor treatments to improve patient outcomes. This research emphasizes the importance of considering the entire health picture, including comorbidities and personal factors, to enhance the quality of life for those with PsA.
-
-
Thank you to the incredible faculty and to IFPA for the opportunity to hold this joint symposium in collaboration with International Psoriasis Council this evening in Stockholm: Pso Bold - Tackling Challenging Issues in Psoriasis and Psoriatic Arthritis. We are incredibly grateful for everyone in attendance as well.
-